{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-036500","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.623807+00:00","generated_at":"2026-06-10T03:34:36.086202+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO","bullets":["Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.","Richie Cunningham appointed CEO and board member; previously CEO of Tyme Technologies and IXC Discovery.","Cunningham receives $450k base salary, time-vesting option for 600k shares (16 quarterly installments), and performance-based option for 140k shares.","Bimal Shah appointed to board and to Audit and Compensation Committees."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-036500","json":"https://secwatch.observer/filing/0001493152-23-036500.json","markdown":"https://secwatch.observer/filing/0001493152-23-036500.md","text":"https://secwatch.observer/filing/0001493152-23-036500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:34:36.086202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f1884e6ef","claim":"Simon Allen departed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7e78446169","claim":"Bimal Shah was appointed as Director at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9a8d7165af","claim":"Richard (Richie) Anthony Cunningham was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}